A Wigan funeral director with 90 years of service is stepping beyond tradition to support a new, life-saving initiative aimed ...
Nia Therapeutics' Smart Neurostimulation System (SNS) is the first device to obtain FDA breakthrough designation for memory ...
Two former Amazon employees stole items worth thousands of dollars from the company’s warehouse on Cortana Place in Baton Rouge, police said.
Artificial intelligence bots are bypassing security controls, stealing secrets, and causing chaos ...
Forty state legislators have sent a letter to the Group Insurance Commission board warning about the public health risks involved with eliminating coverage for GLP-1 weight-loss drugs for obesity — a ...
Reported updated results from 12 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study Presented 24-month follow-up data from Phase 1b ...
Not all vehicles and mobility stocks are created equal. Some are global giants navigating geopolitical headwinds while still raising guidance. Some are cyclical recovery stories with record free cash ...
Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses Research published in Nature ...
Equity-Insider.com News Commentary -- Big money is moving back into biotech. Institutional investors have been writing some of the largest checks in years, with major financing rounds already closing ...
Nigeria has scored zero on obesity treatment and physical activity in a new global assessment of how countries are responding ...
Marvin Slosman, President and CEO, emphasized InspireMD’s momentum in stroke prevention, stating, "I'm extremely proud of our team here at InspireMD and enthusiastic about the impact we are having on ...
Hyperfine, Inc. (NASDAQ:HYPR) Q4 2025 Earnings Call Transcript March 18, 2026 Hyperfine, Inc. beats earnings expectations. Reported EPS is $-0.06276, expectations were $-0.08. Operator: Hello, and ...